Comparison between Tab Tofacitinib and Low-Dose Oral Steroid in Patients Having Vitiligo Over 6 Months

Main Article Content

Reem Fatima
Muhammad Adeel Siddiqui
Hassan Ejaz


Background: Vitiligo is a chronic autoimmune condition characterized by depigmented patches on the skin, presenting significant treatment challenges. Recent studies have focused on the immunomodulatory effects of tofacitinib, a Janus kinase inhibitor, and the anti-inflammatory properties of low-dose oral steroids, yet comparative data on their efficacy and safety are scarce.

Objective: The aim of this study was to compare the efficacy and safety of tofacitinib tablets with low-dose oral steroids in the treatment of vitiligo over a six-month period.

Methods: This descriptive comparative study involved 42 patients with vitiligo, recruited from the Department of Dermatology at the Combined Military Hospital Abbottabad between November 15, 2022, and November 15, 2023. Participants were randomly assigned to receive either tofacitinib tablets (Group A) or low-dose oral steroids (Group B), with adherence monitored through routine follow-ups. The primary outcome measured was the proportion of repigmentation, assessed using standardized photography and Image software, alongside lesion size reduction and the incidence of adverse events. Statistical analyses were performed using SPSS version 25, with p-values ≤0.05 considered significant.

Results: Both groups demonstrated comparable efficacy in terms of repigmentation and lesion size reduction, with no significant difference observed between the tofacitinib (55.8% ± 15.2 repigmentation; 100% lesion size reduction) and low-dose steroid groups (50.2% ± 13.5 repigmentation; 85.71% lesion size reduction) at the 6-month follow-up. The incidence of adverse events was similarly low and statistically non-significant between the two groups.

Conclusion: Tofacitinib and low-dose oral steroids are both effective and safe for the treatment of vitiligo, offering valuable options for patient management. Further research with larger sample sizes and longer follow-up is necessary to confirm these findings and evaluate the long-term outcomes of these treatments.

Article Details

How to Cite
Fatima, R., Siddiqui, M. A., & Ejaz, H. (2024). Comparison between Tab Tofacitinib and Low-Dose Oral Steroid in Patients Having Vitiligo Over 6 Months. Journal of Health and Rehabilitation Research, 4(1), 917–921.
Author Biographies

Reem Fatima, Combined Military Hospital-Abbottabad Pakistan.

Medical Officer, Dermatology.

Muhammad Adeel Siddiqui, Combined Military Hospital–Abbottabad Pakistan.

Consultant Dermatologist & Head of Dermatology Department.

Hassan Ejaz, Combined Military Hospital-Abbottabad Pakistan.

PG-Trainee (FCPS-Internal Medicine).


Yaghoobi R, Omidian M, Bagherani N. Vitiligo: a review of the published work. J Dermatol. 2011 May;38(5):419-31.

Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003 Apr;16(2):90-100.

Abdel‐Malek ZA, Jordan C, Ho T, Upadhyay PR, Fleischer A, Hamzavi I. The enigma and challenges of vitiligo pathophysiology and treatment. Pigment Cell Melanoma Res. 2020 Nov;33(6):778-87.

Razmi TM, Parsad D. Recent advances in pathogenesis and medical management of vitiligo. In: Pigmentary Skin Disorders. 2018. p. 123-38.

Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022 Jan;21(1):21-40.

Diotallevi F, Gioacchini H, De Simoni E, Marani A, Candelora M, Paolinelli M, Molinelli E, Offidani A, Simonetti O. Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art. Int J Mol Sci. 2023 Mar 3;24(5):4910.

Copsel SN, Malek TR, Levy RB. Medical treatment can unintentionally alter the regulatory T-cell compartment in patients with widespread pathophysiologic conditions. Am J Pathol. 2020 Oct 1;190(10):2000-12.

Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA, King B. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol. 2021 Mar 1;147(3):814-26.

Beltrametti SP, Ianniello A, Ricci C. Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review. Ther Clin Risk Manag. 2016 Nov 21:1763-76.

Santiago T, Voshaar M, De Wit M, Carvalho PD, Buttgereit F, Cutolo M, Paolino S, Castelar Pinheiro GR, Boers M, Da Silva JA. Patients’ and rheumatologists’ perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis—an international survey within the GLORIA study. Rheumatology. 2021 Jul 1;60(7):3334-42.

Czarnowicki T, He H, Leonard A, Kim HJ, Kameyama N, Pavel AB, Li R, Estrada Y, Wen HC, Kimmel GW, Kim HJ. Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. J Allergy Clin Immunol. 2019 Jun 1;143(6):2095-107.

Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017 Oct 1;77(4):675-82.

Kubelis López DE, Zapata Salazar NA, Said Fernández SL, Sánchez Domínguez CN, Salinas Santander MA, Martínez Rodríguez HG, Vázquez Martínez OT, Wollina U, Lotti T, Ocampo Candiani J. Updates and new medical treatments for vitiligo. Exp Ther Med. 2021 Aug 1;22(2):1-1.

Perez-Bootello J, Cova-Martin R, Naharro-Rodriguez J, Segurado-Miravalles G. Vitiligo: Pathogenesis and New and Emerging Treatments. Int J Mol Sci. 2023 Dec 9;24(24):17306.

Boyce EG, Vyas D, Rogan EL, Valle-Oseguera CS, O’Dell KM. Impact of tofacitinib on patient outcomes in rheumatoid arthritis–review of clinical studies. Patient Relat Outcome Meas. 2016 Jan 14:1-2.

Huang MY, Armstrong AW. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease. Indian J Dermatol Venereol Leprol. 2023 Sep 5:1-1.

Karagaiah P, Schwartz RA, Lotti T, Wollina U, Grabbe S, Goldust M. Biologic and targeted therapeutics in vitiligo. J Cosmet Dermatol. 2023 Jan;22(1):64-73.

Gupta AK, Wang T, Polla Ravi S, Bamimore MA, Piguet V, Tosti A. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors. J Eur Acad Dermatol Venereol. 2023 Apr;37(4):666-79.

Kurz B, Berneburg M, Bäumler W, Karrer S. Phototherapy: Theory and practice. JDDG: J Dtsch Dermatol Ges. 2023 Aug;21(8):882-97.

Fatani MI, Alkhalifah A, Alruwaili AF, Alharbi AH, Alharithy RA, Khardaly AM, Almudaiheem HY, Al-Jedai A, Eshmawi MT. Diagnosis and Management of Alopecia Areata: a Saudi expert consensus statement (2023). Dermatol Ther. 2023 Oct;13(10):2129-51.

Most read articles by the same author(s)